Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro

Cancer Research

Volumn 48, Issue 20, 1988, Pages 5818-5824

  Weber, Jeffrey S ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CELL CULTURE; CYTOCHEMISTRY; HISTOCHEMISTRY; HISTOLOGY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BIOLOGICAL FACTORS; CYTOKINES; FEMALE; FLOW CYTOMETRY; H-2 ANTIGENS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE I; INTERFERON TYPE II; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR;

EID: 0023806027     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wallich, R., Bulbuc, N., Hammerling. G. J., Katsav, S., Segal, S., and Feldman, M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature (Lond.). 315: 301-303, 1985.
2. Hui, K., Grosveld, F., and Festenstein, H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature (Lond.), 311:750-752, 1984.
3. Tanaka, K., Hayashi. H., Hamada. C., Khoury. G., and Jay, G. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc. Natl. Acad. Sci. USA, 11: 8723-8727. 1986.
4. Weber, J., Jay. G., Tanaka. K., and Rosenberg, S. A. Immunotherapy of a murine tumor with interleukin-2: Increased sensitivity after MHC class I gene transfection. J. Exp. Med., 166: 1716-1733, 1987.
5. Green, W. R., and Phillips, J. D. Differential induction of H2-K vs H-2D class I major histocompatibility complex antigen expression by murine recombinant interferon-γ J. Immunol., 137: 814-818. 1986.
6. Vague, J., White. J., Coleclough, C., Kappala, J., Palmer. E., and Marrack, P. The T cell receptor: The o and ti chains define idiotype, antigen and MHC specificity. Cell. 42: 81-87. 1985.
7. Dembic, Z., Haas. W., Weissl. S., McKubrey, J., Kiefer. H., Von Boehmer, H., and Steinmetz, M. Transfer of specificity by murine α and β T-cell receptor genes. Nature. 320: 232-238. 1986.
8. Lampson, L. A., and Fisher, C. A. Weak HLA and B2-microblobulin expression of neuronal cell lines can be mo'dulated by interferon. Proc. Natl. Acad. Sci. USA. 138:6476-6480. 1984.
9. Pujol-Barrell. R., Todd. I., Doshi, M., Bottazzo. G. F., Sutton, R., Gray, D., Adolf. G. R., and Feldman, M. HLA class II induction in human islet cells by interferon-γ plus tumor necrosis factor or lymphotoxin. Nature (Lond.). 326: 304-306. 1987.
10. Pfizenmaier, K., Scheurich. P., Schluter. C., and Kronke, M. Tumor necrosis factor enhances HLA-A. B, C and DR gene expression in human tumor cells. J. Immunol., 138: 975-980. 1987.
11. Gracomini, P., Aguzzi, A., Pestka, S., Fisher. P. B., and Ferrone, S. Modulation by recombinant DNA leucocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA- and tumor associated antigens by human melanoma cells. J. Immunol., 133: 1649-1655, 1984.
12. Momberg, F., Degeher. T., Bacchus. E., Moldenhauer, G., Hammerling, G. J., and Moller, P. Loss of HLA-A. -B, -C, and de novo expression of HLAD in colorectal cancer. Int. J. Cancer, 37: 179-184. 1986.
13. Moller, P., Herrmann. B., Moldenhauer. G., and Momburg, F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of highgrade malignancy. Int. J. Cancer. 40: 32-39. 1987.
14. Funa, K., Gazdar. A. F., Malison. K., Niiranen. A., Koivinermi. A., Oberg. K., Wilander, E., Doyle. A., and Linnoila, R. I. Interferon-mediated induction of ti 2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clin. Immunol. Immunopathol., 41: 159-164. 1986.
15. Greiner, J. W., Guadagni, F., Naguchi, P., Pestka. S., Colcher, D., Fisher. P. B., and Shlom, J. Recombinant interferon enhances monoclonal antibodytargeting of carcinoma lesions in vivo. Science (Wash. DC). 236: 895-898. 1987.
16. Cameron, R., McLntosh, J. K., and Rosenberg, S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid interferon-o in the treatment of established murin ehepatic metastases.Cancer Res., 48: 5810-5817, 1988.
17. Mule, J. J., Yang. J., Shu, S., and Rosenberg, S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in riro: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J. Immunol., 136: 3899-3909, 1986.
18. Mule, J. J., Shu. S., Schwarz. S. L., and Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Wash. DC), 225: 1487-1489, 1984.
19. Rosenberg, S. A., Grimm, E. A., McGrogan, E. A., Doyle, M., Kawasaki. E., Koths, K., and Mark, D. F. Biological activity of recombinant human interleukin-2 produced in E. coli. Science (Wash. DC), 233: 1412-1414, 1984.
20. Grabstein, K., Eiseman. J., Mochizuki. D., Shanebeck. K., Conlon, P., Hopp. T., March, C., and Gillis, S. Purification to homogeneity of B cell stimulatory factor. A molecule that stimulates proliferation of multiple lymphokine dependent cell lines. J. Exp. Med., 163: 1405-1414, 1986.
21. Ho, M., and Enders, J. F. An inhibitor of viral activity appearing in infected cell cultures. Proc. Natl. Acad. Sci. USA, 45: 385-390, 1959.
22. Larrick, J. W., Brindley. L., and Doyle, M. V. An improved assay for the detection of interleukin-1. J. Immunol. Methods, 79: 39-45, 1985.
23. Ruff, M. R., and Gifford, G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J. Immunol., 125: 1671-1677, 1980.
24. Basham, T. Y., and Merigan, T. C. Recombinant interferon increases HLADR synthesis and expression. J. Immunol., 130: 1492-1498, 1983.
25. Pfizenmaier, K., Scheurich, P., Schlyter, C., and Kronke, M. Tumor necrosis factor enhances HLA-A. -B, -C and -DR gene expression in human tumor cells. J. Immunol., 138: 975-980, 1987.
26. Branca, A. A., and Baglioni, C. Evidence that type 1 and type 11 interferons have different receptors. Nature (Lond.), 294: 768-771. 1981.
27. Weil, J., Epstein. C. J., Epstein, L. B., Sedmak. J. J., Sabran. J. L., and Grossberg, S. E. A unique set of polypeptides is induced by γ interferon in addition to those induced in common with α and β-interferons. Nature (Lond.), 301: 437-440, 1983.
28. Sen, G. C., and Rubin, B. Y. Synthesis of interferon-inducible proteins is regulated differently by interferon α and interferon-γ Virology, 134: 483-490, 1984.
29. Dumont, F. J., and Coker, L. Z. Interferon α/β enhances the expression of Ly-6 antigens on T-cells in vivo and in vitro. Eur. J. Immunol., 16: 735-741, 1986.
30. Quesada, J. R., Hersh, E. M., and Gutterman, J. U. Treatment of hairy cell leukemia with recombinant DNA derived interferon-α: A phase II study. Blood, 68: 493-498. 1986.
31. Talpaz, M., Kantarjian. H. M., McCredie. K., Trujillo, J. M., Keating, M. J., and Gutterman, J. U. Hematologie remission and cytogenetic improvement induced by recombinant human interferon α A in chronic myelogenous leukemia. New Engl. J. Med., 314: 1065-1069. 1986.
32. Creagan, E. T., Ahmann. D. L., Frytak, S., Long, H. J., Chang, M. N., and Itri, L. M. Phase II trials of recombinant leucocyte A interferon in disseminated malignant melanoma: Results in 96 patients. Cancer Treat. Rep., 70: 619-624, 1986.
33. Quasada, J. R., Rios, A., Swanson, D. A., Trown, P., and Gutterman, J. U. Antitumor activity of recombinant derived interferon a in metastatic renal cell cancer. J. Clin. Oncol., 3: 1522-1528. 1985.
34. Brunda, M. J., and Rosenbaum, D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res., 44:597-601,1984.
35. Fidler, I. J., Heicappell, R., Saiki, L., Grutter, G., Horisberger, M. A., and Nuesch, J. Direct antiproliferative effects of recombinant human interferon B/D hybrids on human tumor cell lines. Cancer Res., 47: 2020-2027, 1987.
36. Hicks, N. J., Morris, A. G., and Burke, D. C. Partial reversion of the transformed phenotype of murine sarcoma virus-transformed cells in the presence of interferon: A possible mechanism for the antitumor effect of interferon. J. Cell Sci., 49: 225-236. 1981.
37. Aguet, M., Vignaux, F., Fridman. W. H., and Gresser, I. Enhancement of Fc receptor expression in interferon-treated mice. Eur. J. Immunol., 11: 926-930, 1981.
38. Ruff, M. R., Farrar, W. L., and Pert, C. B. Interferon-α and granulocyte macrophage colony stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small cell cancer lines. Proc. Natl. Acad. Sci. USA, 83: 6613-6617. 1986.
39. Koeffler, H. P., Ranyard. J., Yelton, L., Billing, R., and Bohman, R. γ-Interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells. Proc. Natl. Acad. Sci. USA, 81: 4080-4084, 1984.
40. Velde, A. A., Klomp. J. P. G., Yard. B. A., and Figdor, C. G. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J. Immunol., 140: 1548-1554, 1988.
41. Rosenberg, S. A., Spiess, P., and Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Wash. DC), 233: 1318-1321, 1986.